Evidence map›Paper›PMID 30579240›Full record

ReviewCurrent opinion in immunology2019

Cellular pathways in the development of human and murine innate lymphoid cells.

Steven D Scoville, Aharon G Freud, Michael A Caligiuri

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Group 2 Innate Lymphoid Cells in Allergic Rhinitis.Journal of inflammation research · 2024
    Review
  13. Article
  14. Review
  15. Review
  16. Human natural killer cells: Form, function, and development.The Journal of allergy and clinical immunology · 2023
    Review
  17. Article
  18. ILC3: a case of conflicted identity.Frontiers in immunology · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Steven D ScovilleDepartment of Surgery, The Ohio State University, Columbus, OH, United States.
Aharon G FreudDepartment of Pathology, The Ohio State University, Columbus, OH, United States. Electronic address: aharon.freud@osumc.edu.
Michael A CaligiuriDepartment of Hematology, City of Hope National Medical Center, Los Angeles, CA, United States. Electronic address: mcaligiuri@coh.org.
The Ohio State University · USCity Of Hope National Medical Center · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
TWO SIGNAL REQUIREMENT FOR NATURAL KILLER IMMUNITYP01CA095426 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2002 to 2016
$29.6M
The Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2013 to 2026
$26.0M
Human natural killer cells: Advancing biology and clinical applicationsR35CA210087 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2017 to 2026
$8.3M
IL-15--CHARACTERIZATION THROUGH EXPERIMENTAL IMMUNOLOGYR01CA068458 · NCI · ROSWELL PARK CANCER INSTITUTE · PI CALIGIURI, MICHAEL A, YU, JIANHUA · 1996 to 2019
$4.5M
Elucidation of Human Natural Killer Cell DevelopmentR01CA208353 · NCI · OHIO STATE UNIVERSITY · PI AHARON G FREUD · 2017 to 2026
$4.0M
IL-15 characterization through experimental immunologyR37CA068458 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2010 to 2014
$1.4M
NCI NIH HHS L30 CA199447NCI NIH HHS P01 CA095426NCI NIH HHS P01 CA163205NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA068458NCI NIH HHS R01 CA208353NCI NIH HHS R35 CA210087NCI NIH HHS R37 CA068458
6 · The paper itself

Abstract

Innate lymphoid cells (ILCs) are critical to effective immune surveillance against pathogens, have malignant counterparts, and contribute to disease. Thus, it is important to understand ILC development. All ILCs are derived from the common lymphoid progenitor cell; however, the exact mechanisms and signals that initiate their divergence from T cells, B cells and one and other are incompletely understood. Evidence now supports a stepwise developmental process that includes distinct cellular intermediates, progressively narrowed differentiation, and some plasticity. While the current models of human and murine ILC development share many similarities, they also include some distinct differences. Together these findings have established a working dynamic model of ILC development.

Indexed as

Cell PlasticityImmunity, InnateLymphopoiesisAnimalsCell DifferentiationHumansLymphocytesLymphoid Progenitor CellsMiceModels, ImmunologicalSignal Transduction

Identifiers

PMID30579240
PMCPMC7285385
OpenAlexW2903688858

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.